Navigation Links
DARA Announces Information in Compliance with NASDAQ Rules
Date:4/7/2008

RALEIGH, N.C., April 7, 2008 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today that the audit report accompanying the financial statements for the fiscal year ended December 31, 2007, as included in the Company's Annual Report on 10-K filed on March 31, 2008, contained a going concern qualification. NASDAQ Marketplace Rule 4350(b)(1)(B) requires that a public announcement be made regarding the receipt of an audit opinion that contains a going concern qualification.

In making the announcement, John C. Thomas, Jr., Chief Financial Officer, noted, "Given the financials for the year ended December 31, 2007 reflect Point Therapeutics' operating results and financial position prior to the merger with DARA BioSciences, the going concern qualification was expected. The merger with DARA BioSciences occurred on February 12, 2008 and the first reported results of the merged entity will be on Form 10-Q for the quarter ending March 31, 2008. With that said, it is also important to note that DARA has previously stated that it does intend to seek additional capital during the coming year."

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, and dermatological disorders.

DARA trades on the NASDAQ Global Market under the ticker symbol "DARA".

For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others, the company's ability to raise capital, and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.


'/>"/>
SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
2. VA Announces SGLI and VGLI Premium Reductions
3. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
4. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
5. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
6. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
7. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
8. Smart Balance Announces Sales Organization Appointments
9. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
10. NTMir Announces First International Research Grant for Genome Sequencing
11. Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding ... The following programs will be expanding due to high demand: Master of Business Administration ... will begin this summer. , School of Business Graduate Program Chair Dr. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study ... severe congenital diaphragmatic hernia have better survival rates if surgery is performed early. ... condition where the diaphragm fails to form completely, letting abdominal organs into the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... patented products, announces the Gyrociser, an exercise invention which aids in proper muscle ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
Breaking Medicine Technology: